Profusa (PFSA) and Its Rivals Head to Head Analysis

Profusa (NASDAQ:PFSA) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its rivals? We will compare Profusa to similar companies based on the strength of its profitability, valuation, dividends, earnings, analyst recommendations, risk and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Profusa and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1	0	0	0	1.00
Profusa Competitors	77	77	156	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 47.41%. Given Profusa’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Profusa has less favorable growth aspects than its rivals.

Insider & Institutional Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 11.4% of Profusa shares are held by company insiders. Comparatively, 18.4% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Profusa has a beta of -0.14, suggesting that its share price is 114% less volatile than the S&P 500. Comparatively, Profusa’s rivals have a beta of 1.76, suggesting that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Profusa and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-880.32%
Profusa Competitors	-672.41%	-133.75%	-59.01%

Valuation and Earnings

This table compares Profusa and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Profusa	N/A	-$8.71 million	-0.84
Profusa Competitors	$58.68 million	-$32.15 million	4.23

Profusa’s rivals have higher revenue, but lower earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Profusa rivals beat Profusa on 10 of the 13 factors compared.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.